U.K. Authorizes Pfizer Covid Vaccine for Use in Adolescents
(Bloomberg) -- The U.K. drugs regulator authorized the Covid-19 vaccine from Pfizer Inc. and BioNTech SE for use in 12- to 15-year-olds as a number of countries move to inoculate children in a bid to end the pandemic.
Britain's Medicines and Healthcare products Regulatory Agency said it extended the approval of the vaccine down to adolescents after concluding the shot had a positive safety profile in this age group, according to a statement from the agency Friday. The U.S. and European Union also authorized the vaccine for use in 12- to 15-year-olds last month.
The authorization marks the first green light for a Covid-19 vaccine to be available for use in healthy children under 16 in the U.K. The Pfizer shot was shown to have 100% efficacy in trials of more than 2,000 adolescents and is also being tested in younger children, with plans to trial the vaccine in all ages down to 6-month-old babies. Moderna Inc. also reported 100% efficacy from its adolescent trials last month.
“We have been very careful to take into consideration the younger age group and the benefits of this population being vaccinated against any potential risk of side effects,” said Munir Pirmohamed, chair of the Commission on Human Medicines, which advises the government on vaccines. “Data on neutralizing antibodies showed the vaccine working at the same level as seen in adults aged 16-25 years. These are extremely positive results.”
Following the regulator's approval, the U.K. government has asked its independent panel of experts to advise on whether routine vaccination should be offered to people ages 12 to 17, a spokesperson for the Department of Health and Social Care said in a statement.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.